SB1317 TG02;1204918-72-8 SB 1317;TG 02;SB-1317;TG-02 937270-47-8 TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias. Name: TG02 CAS#: 937270-47-8 Chemical Formula: C23H24N4O Exact Mass: 372.19501 Molecular Weight: 372.46 Elemental Analysis: C, 74.17; H, 6.49; N, 15.04; O, 4.30
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility:
Soluble in DMSO, not in water
Shelf life:
>2 years if stored properly
Drug formulation:
This drug may be formulated in DMSO
Stock solution storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
